The incidence of cancers such as colorectal cancer, head and neck cancer, and melanoma has increased in younger patients. The number of cancer survivors is also increasing in the US. Pairing these facts together, there are many people wi...
Implicit bias affects patient care every day, and not just in oncology. It impacts decision-making in already vulnerable populations such as the historically marginalized racial and ethnic groups, the LGBTQI+ population, patients with di...
Managing infection in patients with neutropenia is a difficult challenge, as fever is often the only clinical symptom. At JADPRO Live 2022, Kyle C. Molina, PharmD, BCIDP, AAVHIP, of the University of Colorado Hospital, discussed the epid...
At JADPRO Live 2022, Jonathan Treem, MD, of the University of Colorado Palliative Care, explained medical aid in dying in order to prepare advanced practitioners to feel confident to counsel a patient who inquiries about aid in dying. He...
The risk of developing venous thromboembolism (VTE) is four to seven times higher in patients with cancer than in those without. At JADPRO Live 2022, presenters discussed risk factors and assessing patients for VTE, as well as how to pro...
Multiple primaries are defined as more than one synchronous or metachronous cancer in the same individual. They can pose challenges to clinicians, as the goal is to find an anticancer therapy strategy that covers both cancer types withou...
In the popular biomarker-focused session at JADPRO Live 2022, presenters paired biomarkers with tumor types for which their expression is most commonly used to determine targeted therapy, identified key assays used to measure common biom...
During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanis...
During JADPRO Live 2022, Jenni Tobin, PharmD, reviewed the indications of newly approved therapies in hematologic malignancies (including those for multiple myeloma, lymphoma, and acute leukemia) approved from late 2021 to late 2022. Dr....
During JADPRO Live 2022, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP, discussed investigational therapeutic agents in the drug development pipeline. Dr. Moore highlighted agents that represent either a new drug class, a novel mechani...
The treatment paradigm for metastatic non–small cell lung cancer has changed significantly since the advent of targeted therapy. During JADPRO Live 2022, presenters focused on important updates to clinical practice guidelines, data from ...
HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters di...
Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations th...
